Home
Ocugen

Ocugen Market Share Analysis for August 2026

Reach Ocugen’s team for information on partnerships or general inquiries. Our experts are ready to guide, support, and connect with you.

Health > Biotechnology and Pharmaceuticals

Domainocugen.com

Year Founded2013

Employees51 - 200

Annual Revenue$10M - $15M

Ocugen

Ocugen (including company regionals)

ocugen.com

See more website traffic and engagement information

Ocugen Revenue up to August 2026 is 10M - 15M

revenue generated by Ocugen top domains

Ocugen top domains revenue over 3 years

Revenue for Ocugen top domains

ocugen.com10M - 15M

See more with Sales Intelligence

Total visits to Ocugen's top domains

Understand Ocugen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ocugen.com11.4K

See more with Sales Intelligence

Avg. visit duration in Ocugen's top domains

Analyze Ocugen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ocugen.com00:00:05

See more with Sales Intelligence

Avg. pageviews on Ocugen's top domains

See how Ocugen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ocugen.com1.63

See more with Sales Intelligence

Ocugen top competitors by domain

Top similar sites in August 2026, ranked by their affinity

cgtlive.comCompany NameCGTLiveEmployees501 - 1000HQUnited States, New Jersey, CranburyAnnual revenue--Total visits22.2KHealth > Health Conditions and Concerns

Top technologies used by Ocugen

These are the website technologies, by industry, used by Ocugen top domains

Advertising (6)

Google Adsense

Widget (5)

Twemoji

Audio Video Media (3)

YouTube

Conversion & Analytics (3)

Google Analytics

More Technologies

10

See all

News & Signals from Ocugen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOcugen is developing treatments using the RORA modifier gene.For Stargardt disease and geographic atrophy, Ocugen is developing treatments using the RORA modifier gene.

NewsOcugen had revenue of $1.49M on Jul 1st '26.* Ocugen reported a quarterly loss of $0.07 per share, missing the $0.05 consensus estimate, while revenue of $1.49 million exceeded analysts' $0.89 million forecast.